In Silico Analysis of Bioactive Compounds From Moringa Oleifera Leaves For Inhibiting The Latent Membrane Protein-1 (LMP-1) of The Epstein–Barr Virus Which Causes Nasopharyngeal Cancer

Authors

DOI:

https://doi.org/10.59278/cbs.v5i14.110

Keywords:

Bioactive compounds, Epstein-Barr virus, in silico screening, Latent Membrane Protein-1 (LMP1, Moringa oleifera, Nasopharyngeal carcinoma

Abstract

Background: Nasopharyngeal carcinoma (NPC), closely linked to Epstein-Barr virus (EBV) infection, is prevalent in Southeast Asia, with EBV's Latent Membrane Protein-1 (LMP1) playing a crucial role in cancer progression. The current treatment options for NPC are limited, and the need for novel therapeutic strategies targeting LMP1 is urgent. Aim: This study employed in silico approaches to identify potential LMP1 inhibitors from Moringa oleifera bioactive compounds. Protein structure prediction was performed using AlphaFold, followed by binding site identification using PrankWeb.cz. Molecular docking analysis was carried out using PLANTS software to assess the binding affinity of selected compounds. QSAR analysis was used to correlate molecular descriptors with biological activity. Results: The study found that compounds such as Thiamine and Indole-3-Acetonitrile exhibited strong binding affinities with LMP1, demonstrated by low docking scores (e.g., Thiamine: -57.951). The QSAR analysis further revealed favorable properties for these compounds, suggesting good bioavailability and potential for LMP1 inhibition. Conclusion:  This study successfully identified promising Moringa oleifera compounds as potential inhibitors of LMP1 in EBV-associated NPC using computational tools. These findings provide a foundation for future experimental validation and the development of natural product-based therapies for EBV-related cancers.

References

1. Evita Zevanya, Iswarini AD. Karsinoma Nasofaring: Faktor Risiko, Deteksi Dini, Diagnosis, dan Tata Laksana. Cermin Dunia Kedokteran. 2025 Jul 7;52(7):460–70. doi:10.55175/cdk.v52i7.1334

2. Indrasari SR, Dewi. Afriani Yussy, Luetta NA, Romdhoni AC, Nuaba IGA, Herawati C, et al. Epidemiological and Clinical Profile of Nasopharyngeal Carcinoma in Indonesia: A Nationwide Descriptive Study. International Journal of Biomedicine. 2025 Sep 10;15(3). doi:10.21103/Article15(3)_OA9

3. Su ZY, Siak PY, Leong CO, Cheah SC. The role of Epstein–Barr virus in nasopharyngeal carcinoma. Front Microbiol. 2023 Feb 9;14. doi:10.3389/fmicb.2023.1116143

4. Yoshizaki T, Kondo S, Endo K, Nakanishi Y, Aga M, Kobayashi E, et al. Modulation of the tumor microenvironment by Epstein‐Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. Cancer Sci. 2018 Feb 21;109(2):272–8. doi:10.1111/cas.13473

5. Salano VE, Mwakigonja AR, Abdulshakoor A, Kahinga AA, Richard EM. Epstein-Barr Virus Latent Membrane Protein-1 Expression in Nasopharyngeal Carcinoma. JCO Glob Oncol. 2021 Dec;(7):1406–12. doi:10.1200/GO.21.00120

6. Natasha Khairunnisa Ardanianti, Achmad Chusnu Romdhoni, Betty Agustina Tambunan. Association of LMP1 expression and cancer stage of nasopharyngeal carcinoma patients at Dr. Soetomo Regional General Hospital in January 2023 – December 2023. World Journal of Advanced Research and Reviews. 2025 Sep 30;27(3):846–53. doi:10.30574/wjarr.2025.27.3.3210

7. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence,signs, and symptoms at presentation. Chin J Cancer. 2012 Apr 5;31(4):185–96. doi:10.5732/cjc.011.10328

8. Chua MLK, Zhang X, Wong KCW, Marret G, Spreafico A, Ma B. Updates on Treatments and Management of Nasopharyngeal Carcinoma. American Society of Clinical Oncology Educational Book. 2025 Jun;45(3). doi:10.1200/EDBK-25-472460

9. Salam DSDA, San HS, Wezen XC. Computational identification of PTPRJ peptide targeting the Epstein Barr virus latent membrane protein 1. Sci Rep. 2025 Oct 7;15(1):34940. doi:10.1038/s41598-025-18741-0

10. Abro F, Kumar N, Nitasha, Kumari S, Qazi S, Khan MS, et al. Harnessing the anticancer potential of Moringa oleifera: a safer, multi-targeted adjunct. Annals of Medicine & Surgery. 2025 Dec;87(12):7923–5. doi:10.1097/MS9.0000000000004227

11. Rajkumar C, Ramsridhar S, Veeraraghavan VP, Francis AP, Purushotham M, Mageshwari U. Anticancer effect of Moringa oleifera in oral squamous cell carcinoma: a systematic review. Discover Oncology. 2024 Nov 21;15(1):688. doi:10.1007/s12672-024-01557-1

12. Budhy TI, Adam D, Azis ZMR, Syahputri V, Yuliani MGA, Suwarto MFS, et al. The Potential of Moringa Leaf Nanoparticles (Moringa oleifera) on the Expression of TNFα, IL10, and HSP 27 in Oral Cavity Cancer. Journal of Multidisciplinary Applied Natural Science. 2023 Nov 22;4(1):120–9. doi:10.47352/jmans.2774-3047.198

13. Sivani BM, Venkatesh P, Murthy TPK, Kumar SB. In silico screening of antiviral compounds from Moringa oleifera for inhibition of SARS-CoV-2 main protease. Current Research in Green and Sustainable Chemistry. 2021;4:100202. doi:10.1016/j.crgsc.2021.100202

14. Masarkar N, Pal M, Roy M, Yadav AK, Pandya B, Lokhande S, et al. In-Silico screening of bioactive compounds of Moringa oleifera as potential inhibitors targeting HIF-1α/VEGF/GLUT-1 pathway against breast cancer. J Complement Integr Med. 2025 Mar 13;22(1):149–64. doi:10.1515/jcim-2024-0176

15. Bumulo N, Aman LO, Kilo J La, La Kilo A, Salimi YK, Arviani A. In Silico Study of the Potential of Moringa oleifera Secondary Metabolites as α-Glucosidase Inhibitors. Indonesian Journal of Pharmaceutical Education. 2025 Feb 26;5(1). doi:10.37311/ijpe.v5i1.28749

16. Susantiningsih T, Baihaki I, Thadeaus MS, Setyaningsih Y, Citrawati M. In-Silico Study of Bioactive Compounds from Moringa oleifera Fruit as Anti Premature Senescence Agents in Cardiac Cells: A Study on the p53 Protein. Pharmacognosy Journal. 2025 Sep 19;17(4):497–505. doi:10.5530/pj.2025.17.62

17. Kumar BK, Faheem, Sekhar KVGC, Ojha R, Prajapati VK, Pai A, et al. Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases. J Biomol Struct Dyn. 2022 Feb 11;40(3):1363–86. doi:10.1080/07391102.2020.1824814

18. Xiong Y, Cheng F, Zhang J, Su H, Hu H, Zou Y, et al. Structure-based design of a novel inhibitor of the ZIKA virus NS2B/NS3 protease. Bioorg Chem. 2022 Nov;128:106109. doi:10.1016/j.bioorg.2022.106109

19. Zhang S, Krumberger M, Morris MA, Parrocha CMT, Kreutzer AG, Nowick JS. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists. Eur J Med Chem. 2021 Jun;218:113390. doi:10.1016/j.ejmech.2021.113390

20. Song F, Sun H, Ma X, Wang W, Luan M, Zhai H, et al. QSAR and molecular docking studies on designing potent inhibitors of SARS-CoVs main protease. Front Pharmacol. 2023 May 5;14. doi:10.3389/fphar.2023.1185004

Downloads

Published

2026-10-31 — Updated on 2026-11-18

Versions

Issue

Section

Articles

How to Cite

In Silico Analysis of Bioactive Compounds From Moringa Oleifera Leaves For Inhibiting The Latent Membrane Protein-1 (LMP-1) of The Epstein–Barr Virus Which Causes Nasopharyngeal Cancer. (2026). International Journal of Cell and Biomedical Science, 5(14), 558-569. https://doi.org/10.59278/cbs.v5i14.110 (Original work published 2026)